Developer docs
API playgroundTry for free, no card

Search company profiles

BGI Group

Full company profile

uuid0002xpv

Namestring
BGI Group
Legal namestring
华大集团
Websiteurl
genomics.cn
Company typeenum
Private
Founded yearint
1999
Descriptiontext

BGI Group (华大集团) is a Chinese multinational genomics conglomerate founded in 1999 and headquartered in Shenzhen, operating as one of the world's largest DNA sequencing service providers. The company is structured around vertically integrated subsidiaries including BGI Genomics (SZSE: 300676, clinical and scientific services), MGI Tech (SSE STAR: 688114, sequencing instruments and reagents), and a network of specialized units spanning spatiotemporal omics (Stereo-seq), nanopore sequencing (CycloneSEQ), forensic identification, IVD diagnostics, cell technology, synthetic biology, and consumer health products. Its multi-omics technology platform combines proprietary DNA Nanoball sequencing (DNBSEQ series), spatial transcriptomics with subcellular resolution, long-read nanopore technology, automated laboratory systems, mass spectrometry-based proteomics and metabolomics, and AI/machine learning integration including the Genos billion-parameter human genome foundation model. Operations span more than 100 countries with research and manufacturing facilities across China (Shenzhen, Beijing, Hangzhou, Qingdao, Sanya, Shanghai, Harbin) and an Ethiopia-based COVID-19 test kit manufacturing facility.

Short descriptiontext

BGI Group is a Shenzhen-headquartered, vertically integrated genomics conglomerate offering sequencing instruments, multi-omics services, clinical diagnostics, and AI-driven bioinformatics to research institutions, hospitals, governments, and consumers across 100+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersShenzhen, China
HQ citystring
Shenzhen
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices9 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genomic sequencing services, DNA sequencing instruments, clinical genetic testing, spatial transcriptomics, multi-omics analysis
Industry6 codes
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAGAOAB
Data Management, Biostatistics & Statistical Programming FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical and Diagnostic Laboratories6215
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Genomics and multi-omics services
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model6 records
1Scientific Research and Technology Services
TypeProfessional Services
Description

Provides comprehensive genomic sequencing, bioinformatics analysis, proteomics, metabolomics, and other omics services to research institutions, universities, and biotechnology companies globally. Services include whole genome sequencing, exome sequencing, single-cell sequencing, and custom omics solutions.

genomics.cn
2Clinical and Medical Testing Services
TypeProfessional Services
Description

Clinical genetic testing services including NIFTY non-invasive prenatal testing, tumor testing, infectious disease testing (PMseq), newborn screening, and reproductive health testing. Services provided through hospitals, clinics, and directly to patients.

genomics.cn
3Sequencing Instruments and Consumables
TypeHardware Sales
Description

Sale of DNBSEQ series sequencing instruments, automated sample preparation systems, and related reagents and consumables through MGI Tech subsidiary.

genomics.cn
4In Vitro Diagnostic Products
TypeOne Time License
Description

Development and sale of IVD reagents including tumor markers, infectious disease tests, fertility tests, and genetic testing kits.

genomics.cn
5Consumer Health Products
TypeHardware Sales
Description

Consumer-facing genetic testing products including handheld genetic testing devices (alcohol metabolism assessment kits), cosmetic formulations, and pet genetics services as part of expansion into everyday health markets.

genomics.cn
6Judicial/Forensic Identification Services
TypeProfessional Services
Description

DNA kinship testing, animal/plant testing, and poison detection services through BGI Identification subsidiary.

genomics.cn
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain
Pricing details1 tier
1Enterprise/Institutional Services
ModelSubscriptionBilling cadenceAnnual
Notes

B2B contracts with research institutions, hospitals, and pharmaceutical companies typically involve project-based or annual service agreements with volume-based pricing.

genomics.cn
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 9 records shown
1华大基因 (BGI Genomics)
Description

Global leading scientific technology services provider and precision medical services operator, listed on Shenzhen Stock Exchange

genomics.cn
+8 more records
Core offering1 text field

BGI Group operates a vertically integrated genomics and multi-omics platform spanning proprietary DNA sequencing instruments (DNBSEQ, CycloneSEQ nanopore), spatial transcriptomics (Stereo-seq), clinical genetic testing services (NIFTY non-invasive prenatal test, PMseq pathogen detection), reproductive and newborn genetic screening, AI-driven bioinformatics (AlphaLab, MegaBOLT, Genos), and AI-empowered laboratory automation through the Huo-Yan network. The company also produces IVD reagent products and serves agricultural applications through BGI Agriculture.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • BGI's gene sequencing contribution exceeds 50% of global output (Harvard geneticist George Church)
+3 more records
Product overview1 text field

BGI Group is a globally leading life science genomics company offering an integrated platform spanning gene sequencing hardware, multi-omics technologies, and AI-powered bioinformatics solutions. The product portfolio includes ultra-high-throughput sequencing instruments (DNBSEQ-T20×2, DNBSEQ-T7+), medium and small sequencers (DNBSEQ-G99, DNBSEQ-E25, T1+), nanopore technology (CycloneSEQ), spatial transcriptomics (Stereo-seq), automated sample preparation systems (MGISP series), and clinical genetic testing services (NIFTY®, PMseq®, EmbryoSeq, SeqHPV®). The company provides both instrument platforms and consumable reagents along with AI-enabled data analysis software including AlphaLab™ Studio management platform, MegaBOLT bioinformatics accelerator, and the Genos foundation model. Services span reproductive health, oncology precision medicine, infectious disease detection, and population genomics research.

Product and service1 record
1DNBSEQ-T20×2 Gene Sequencer
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-13
Description

Omics Empower launched Xenium In Situ Spatial Transcriptomics services at its Hong Kong Science Park laboratory, becoming the second facility in Hong Kong to operate the 10x Genomics-developed platform. The laboratory supports both 10x Genomics Visium and BGI Group's Stereo-seq technologies, expanding local access to high-resolution spatial transcriptomics capabilities across the Asia-Pacific region.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

BGI Life Science Research Institute collaborated with Stanford University School of Medicine and other institutions to publish research in Cell magazine, developing the Stereo-seq algorithm toolkit that marks a revolutionary breakthrough in spatiotemporal omics research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-initiated the ICPBM (International Collaborative Primate Brain Mapping) project, a 25-year global collaboration to create detailed maps of primate and human brains. Multiple joint research projects in genomics and life sciences conducted.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

BGI has deployed Huo-Yan (Fire Eye) laboratories and COVID-19 testing capabilities across Belt and Road countries, establishing international health cooperation partnerships. Conducted training programs for health professionals from multiple developing nations.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint research on primate brain cell mapping, non-human primate brain cell atlas, and cerebellum spatiotemporal research. Multiple high-impact joint publications in Nature and Cell journals.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Earth BioGenome Project (EBP), Thousand Plant Genomes Project (10KP), Thousand Bird Genomes Project (B10K), Thousand Fish Genomes Project (F10K) - co-initiated with international partners including Smithsonian Institution and others.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

BGI Group is expanding AI footprint in Africa as part of China's AI competition strategy. African countries are leveraging partnerships from both China and US, using dual-engagement strategies to navigate great power competition.

8Southeast Asian CDMOs
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Chinese biopharma companies including BGI Group have accelerated engagement in Southeast Asia through COVID-19 vaccine partnerships, genomic collaborations, and investments to diversify supply chains amid US Biosecure Act restrictions.

carnegieendowment.org
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Huo-Yan laboratories established international partnerships in Serbia, Brunei, Philippines and other countries. COVID-19 test kit manufacturing facility established in Ethiopia with annual capacity of 10 million kits.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

World's leading DNA sequencing platform company; develops sequencers (NovaSeq, NextSeq, MiSeq) and reagents serving the same research, clinical, and pharma customers as BGI. Illumina is BGI's primary head-to-head competitor in short-read sequencing, particularly after Illumina acquired the early BGI-related IP that triggered a long-running patent dispute.

TypeDirect peer
Description

Developer of HiFi long-read sequencing technology (Sequel IIe, Revio). Competes with BGI's CycloneSEQ nanopore and DNBSEQ platforms for long-read applications in de novo assembly, full-length transcriptomics, and clinical rare disease research.

TypeDirect peer
Description

Direct nanopore sequencing competitor with MinION, GridION, and PromethION platforms. Oxford Nanopore competes head-to-head with BGI's CycloneSEQ-WT02 and CycloneSEQ-WY01 in long-read genomics and real-time sequencing applications.

TypeDirect peer
Description

Single-cell and spatial transcriptomics platform provider (Chromium, Visium, Xenium). Directly competes with BGI's Stereo-seq, Stereo-cell, and DNBelab D4 platforms in single-cell sequencing and spatial omics markets.

TypeBroad incumbent
Description

Broad life science tools incumbent offering Ion Torrent sequencing, capillary electrophoresis (Sanger), qPCR, mass spectrometry, and clinical diagnostics. Overlaps with BGI across sequencing instruments, clinical testing services, and bioinformatics but addresses a much wider portfolio.

TypeEmerging player
Description

Mid-throughput sequencing competitor with AVITI platform offering novel avidity-based chemistry. Targets the same mid-throughput segment as BGI's DNBSEQ-G99 and is expanding into higher throughput - emerging pricing threat to BGI.

TypeBroad incumbent
Description

Molecular biology sample technologies, NGS library prep, and bioinformatics (Ingenuity, QIAseq). Competes with BGI's MGISP automated sample prep, nucleic acid extraction instruments, and bioinformatics tools in the sample-to-data workflow.

TypeBroad incumbent
Description

Provides analytical instruments, genomics consumables (SureSelect, Tapestation), and bioinformatics. Overlaps with BGI's laboratory automation, NGS library prep, and clinical diagnostics capabilities.

TypeDirect peer
Description

Beijing-based sequencing services provider offering whole genome, exome, single-cell, and multi-omics services to global research and pharma customers. Most direct services peer to BGI Genomics; also recently added to the US Section 1260H list alongside BGI.

TypeEmerging player
Description

Clinical sequencing and ImmunoID NeXT platform for tumor profiling and pharma services. Competes with BGI Genomics in clinical tumor testing, especially for pharma clinical trials and immuno-oncology biomarker discovery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries13 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment14 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BGI Group

Genomics and multi-omics servicesgenomics.cn

BGI Group is a Shenzhen-headquartered, vertically integrated genomics conglomerate offering sequencing instruments, multi-omics services, clinical diagnostics, and AI-driven bioinformatics to research institutions, hospitals, governments, and consumers across 100+ countries.

What BGI Group does

BGI Group (华大集团) is a Chinese multinational genomics conglomerate founded in 1999 and headquartered in Shenzhen, operating as one of the world's largest DNA sequencing service providers. The company is structured around vertically integrated subsidiaries including BGI Genomics (SZSE: 300676, clinical and scientific services), MGI Tech (SSE STAR: 688114, sequencing instruments and reagents), and a network of specialized units spanning spatiotemporal omics (Stereo-seq), nanopore sequencing (CycloneSEQ), forensic identification, IVD diagnostics, cell technology, synthetic biology, and consumer health products. Its multi-omics technology platform combines proprietary DNA Nanoball sequencing (DNBSEQ series), spatial transcriptomics with subcellular resolution, long-read nanopore technology, automated laboratory systems, mass spectrometry-based proteomics and metabolomics, and AI/machine learning integration including the Genos billion-parameter human genome foundation model. Operations span more than 100 countries with research and manufacturing facilities across China (Shenzhen, Beijing, Hangzhou, Qingdao, Sanya, Shanghai, Harbin) and an Ethiopia-based COVID-19 test kit manufacturing facility.

BGI Group firmographics

Firmographics
Name
BGI Group
Legal name
华大集团
Website
https://genomics.cn
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
101–250 employees
Short description
BGI Group is a Shenzhen-headquartered, vertically integrated genomics conglomerate offering sequencing instruments, multi-omics services, clinical diagnostics, and AI-driven bioinformatics to research institutions, hospitals, governments, and consumers across 100+ countries.
Ownership category
akta.pro rank

BGI Group industry classification

Industry
Product category
Genomics and multi-omics services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAFAMAH
Genetic & Prenatal Testing Laboratories
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAFAI
Microbiome Analytics, Sequencing & Bioinformatics Platforms
SECONDARYHLAGAOAB
Data Management, Biostatistics & Statistical Programming FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)

Keywords

  • Genomic sequencing services
  • DNA sequencing instruments
  • Clinical genetic testing
  • Spatial transcriptomics
  • Multi-omics analysis

Where BGI Group is headquartered

Location

Headquarters

HQ city
Shenzhen
HQ country
China
HQ region
Asia

Offices9 records

Markets served

BGI Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Scientific Research and Technology Services: Provides comprehensive genomic sequencing, bioinformatics analysis, proteomics, metabolomics, and other omics services to research institutions, universities, and biotechnology companies globally. Services include whole genome sequencing, exome sequencing, single-cell sequencing, and custom omics solutions.
  2. Clinical and Medical Testing Services: Clinical genetic testing services including NIFTY non-invasive prenatal testing, tumor testing, infectious disease testing (PMseq), newborn screening, and reproductive health testing. Services provided through hospitals, clinics, and directly to patients.
  3. Sequencing Instruments and Consumables: Sale of DNBSEQ series sequencing instruments, automated sample preparation systems, and related reagents and consumables through MGI Tech subsidiary.
  4. In Vitro Diagnostic Products: Development and sale of IVD reagents including tumor markers, infectious disease tests, fertility tests, and genetic testing kits.
  5. Consumer Health Products: Consumer-facing genetic testing products including handheld genetic testing devices (alcohol metabolism assessment kits), cosmetic formulations, and pet genetics services as part of expansion into everyday health markets.
  6. Judicial/Forensic Identification Services: DNA kinship testing, animal/plant testing, and poison detection services through BGI Identification subsidiary.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise/Institutional Services

Go-to-market motion2 records

Distribution channels6 records

Marketing channels9 records

BGI Group product offering

Product offering

Core offering

BGI Group operates a vertically integrated genomics and multi-omics platform spanning proprietary DNA sequencing instruments (DNBSEQ, CycloneSEQ nanopore), spatial transcriptomics (Stereo-seq), clinical genetic testing services (NIFTY non-invasive prenatal test, PMseq pathogen detection), reproductive and newborn genetic screening, AI-driven bioinformatics (AlphaLab, MegaBOLT, Genos), and AI-empowered laboratory automation through the Huo-Yan network. The company also produces IVD reagent products and serves agricultural applications through BGI Agriculture.

Product overview

BGI Group is a globally leading life science genomics company offering an integrated platform spanning gene sequencing hardware, multi-omics technologies, and AI-powered bioinformatics solutions. The product portfolio includes ultra-high-throughput sequencing instruments (DNBSEQ-T20×2, DNBSEQ-T7+), medium and small sequencers (DNBSEQ-G99, DNBSEQ-E25, T1+), nanopore technology (CycloneSEQ), spatial transcriptomics (Stereo-seq), automated sample preparation systems (MGISP series), and clinical genetic testing services (NIFTY®, PMseq®, EmbryoSeq, SeqHPV®). The company provides both instrument platforms and consumable reagents along with AI-enabled data analysis software including AlphaLab™ Studio management platform, MegaBOLT bioinformatics accelerator, and the Genos foundation model. Services span reproductive health, oncology precision medicine, infectious disease detection, and population genomics research.

Differentiator

Problem solved

Functional benefit

Brands

  • 华大基因 (BGI Genomics): Global leading scientific technology services provider and precision medical services operator, listed on Shenzhen Stock Exchange
  • 华大智造 (MGI Tech)
  • NIFTY
  • 火眼实验室 (HuoYan Labs)
  • PMseq
  • EmbryoSeq
  • Stereo-seq
  • GigaScience
  • Stereo-cell

Products and services

  • DNBSEQ-T20×2 Gene Sequencer

Quantifiable outcome

  • BGI's gene sequencing contribution exceeds 50% of global output (Harvard geneticist George Church)
  • +3 more outcomes

Companies that use BGI Group

Customer profile

Named customers6 records

Segments6 records

Ideal customer profiles5 records

BGI Group technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature8 records

BGI Group partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • Omics EmpowercoreStrategic or Co-development Partner · 13 February 2026Omics Empower launched Xenium In Situ Spatial Transcriptomics services at its Hong Kong Science Park laboratory, becoming the second facility in Hong Kong to operate the 10x Genomics-developed platform. The laboratory supports both 10x Genomics Visium and BGI Group's Stereo-seq technologies, expanding local access to high-resolution spatial transcriptomics capabilities across the Asia-Pacific region.
  • Stanford University School of MedicinecoreStrategic or Co-development PartnerBGI Life Science Research Institute collaborated with Stanford University School of Medicine and other institutions to publish research in Cell magazine, developing the Stereo-seq algorithm toolkit that marks a revolutionary breakthrough in spatiotemporal omics research.
  • Chinese Academy of SciencescoreStrategic or Co-development PartnerCo-initiated the ICPBM (International Collaborative Primate Brain Mapping) project, a 25-year global collaboration to create detailed maps of primate and human brains. Multiple joint research projects in genomics and life sciences conducted.
  • Belt and Road Countries Government Health ProgramscoreStrategic or Co-development PartnerBGI has deployed Huo-Yan (Fire Eye) laboratories and COVID-19 testing capabilities across Belt and Road countries, establishing international health cooperation partnerships. Conducted training programs for health professionals from multiple developing nations.
  • Chinese Academy of Sciences Brain Science and Intelligence Technology Excellence Innovation CentercoreStrategic or Co-development PartnerJoint research on primate brain cell mapping, non-human primate brain cell atlas, and cerebellum spatiotemporal research. Multiple high-impact joint publications in Nature and Cell journals.
  • Multiple International Research InstitutionsminorStrategic or Co-development PartnerEarth BioGenome Project (EBP), Thousand Plant Genomes Project (10KP), Thousand Bird Genomes Project (B10K), Thousand Fish Genomes Project (F10K) - co-initiated with international partners including Smithsonian Institution and others.
  • African Countries (Kenya, South Africa, Nigeria, Rwanda, Mauritius, Egypt)minorStrategic or Co-development PartnerBGI Group is expanding AI footprint in Africa as part of China's AI competition strategy. African countries are leveraging partnerships from both China and US, using dual-engagement strategies to navigate great power competition.
  • Southeast Asian CDMOsminorChannel Partner/ Reseller/ DistributorChinese biopharma companies including BGI Group have accelerated engagement in Southeast Asia through COVID-19 vaccine partnerships, genomic collaborations, and investments to diversify supply chains amid US Biosecure Act restrictions.
  • Global Healthcare OrganizationscoreChannel Partner/ Reseller/ DistributorHuo-Yan laboratories established international partnerships in Serbia, Brunei, Philippines and other countries. COVID-19 test kit manufacturing facility established in Ethiopia with annual capacity of 10 million kits.

Scale indicators12 records

Recent moves7 records

Expansion highlights7 records

BGI Group competitors and assessment

Company assessment

Direct peers

  • Illumina: World's leading DNA sequencing platform company; develops sequencers (NovaSeq, NextSeq, MiSeq) and reagents serving the same research, clinical, and pharma customers as BGI. Illumina is BGI's primary head-to-head competitor in short-read sequencing, particularly after Illumina acquired the early BGI-related IP that triggered a long-running patent dispute.
  • Pacific Biosciences: Developer of HiFi long-read sequencing technology (Sequel IIe, Revio). Competes with BGI's CycloneSEQ nanopore and DNBSEQ platforms for long-read applications in de novo assembly, full-length transcriptomics, and clinical rare disease research.
  • Oxford Nanopore Technologies: Direct nanopore sequencing competitor with MinION, GridION, and PromethION platforms. Oxford Nanopore competes head-to-head with BGI's CycloneSEQ-WT02 and CycloneSEQ-WY01 in long-read genomics and real-time sequencing applications.
  • 10x Genomics: Single-cell and spatial transcriptomics platform provider (Chromium, Visium, Xenium). Directly competes with BGI's Stereo-seq, Stereo-cell, and DNBelab D4 platforms in single-cell sequencing and spatial omics markets.
  • Novogene: Beijing-based sequencing services provider offering whole genome, exome, single-cell, and multi-omics services to global research and pharma customers. Most direct services peer to BGI Genomics; also recently added to the US Section 1260H list alongside BGI.

Broad incumbents

  • Thermo Fisher Scientific: Broad life science tools incumbent offering Ion Torrent sequencing, capillary electrophoresis (Sanger), qPCR, mass spectrometry, and clinical diagnostics. Overlaps with BGI across sequencing instruments, clinical testing services, and bioinformatics but addresses a much wider portfolio.
  • Qiagen: Molecular biology sample technologies, NGS library prep, and bioinformatics (Ingenuity, QIAseq). Competes with BGI's MGISP automated sample prep, nucleic acid extraction instruments, and bioinformatics tools in the sample-to-data workflow.
  • Agilent Technologies: Provides analytical instruments, genomics consumables (SureSelect, Tapestation), and bioinformatics. Overlaps with BGI's laboratory automation, NGS library prep, and clinical diagnostics capabilities.

Emerging players

  • Element Biosciences: Mid-throughput sequencing competitor with AVITI platform offering novel avidity-based chemistry. Targets the same mid-throughput segment as BGI's DNBSEQ-G99 and is expanding into higher throughput - emerging pricing threat to BGI.
  • Personalis: Clinical sequencing and ImmunoID NeXT platform for tumor profiling and pharma services. Competes with BGI Genomics in clinical tumor testing, especially for pharma clinical trials and immuno-oncology biomarker discovery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

BGI Group social profiles

Digital presence

BGI Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BGI Group leadership team

Management profile

Number of profiles

Profiles13 records

BGI Group subsidiaries and ownership

Company hierarchy

Subsidiaries13 records

BGI Group funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BGI Group M&A and investment

M&A and investment

M&A1 record

Investments14 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BGI Group

What does BGI Group do?

BGI Group operates a vertically integrated genomics and multi-omics platform spanning proprietary DNA sequencing instruments (DNBSEQ, CycloneSEQ nanopore), spatial transcriptomics (Stereo-seq), clinical genetic testing services (NIFTY non-invasive prenatal test, PMseq pathogen detection), reproductive and newborn genetic screening, AI-driven bioinformatics (AlphaLab, MegaBOLT, Genos), and AI-empowered laboratory automation through the Huo-Yan network. The company also produces IVD reagent products and serves agricultural applications through BGI Agriculture.

Is BGI Group a public or private company?

BGI Group is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was BGI Group founded?

BGI Group was founded in 1999. It employs 101 to 250 people.

Where is BGI Group based?

BGI Group is headquartered in Shenzhen, China, in the Asia region.

How does BGI Group make money?

Six revenue lines are on record. Scientific Research and Technology Services are the primary driver. The others are clinical and Medical Testing Services, sequencing Instruments and Consumables, in Vitro Diagnostic Products, consumer Health Products and judicial/Forensic Identification Services.

Who are BGI Group's main competitors?

Direct peers on record are Illumina, Pacific Biosciences, Oxford Nanopore Technologies, 10x Genomics and Novogene. Broad incumbents are Thermo Fisher Scientific, Qiagen and Agilent Technologies. Emerging players are Element Biosciences and Personalis.

Does BGI Group have an API?

No public API is recorded for BGI Group.

What industry is BGI Group in?

BGI Group's product category is Genomics and multi-omics services. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays), with a secondary code of HLAFAMAH, Genetic & Prenatal Testing Laboratories. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PedailyClaude新模型更新,卖铲人龙头赢麻了Anthropic released Claude Fable 5.2 and Claude Mythos 5.2 models with a 264-page System Card covering life sciences, including RNA design, gene therapy, and drug ADME prediction. The card suggests model capabilities define industrial division of labor, compressing human and software premiums in well-performing areas. BGI Genomics is positioned at both ends of the omics research chain.JiemianBGI Genomics and Pengbo Boron Neutron signed a strategic cooperation agreement.BGI Genomics signed a strategic cooperation agreement with Pengbo Boron Neutron on November 8 at the 9th China International Import Expo. The partnership aims to integrate genetic technology with Boron Neutron Capture Therapy for an innovative 'integrated diagnosis and treatment' model for tumors.Business & FinancialHigh-Fidelity Long-Read Sequencing Market Global Report 2026 High-Fidelity Long-Read Sequencing Market Poised To Reach $4.22 Billion By 2030The global high-fidelity long-read sequencing market is projected to grow from $1.53 billion in 2025 to $1.88 billion in 2026, a CAGR of 22.2%, and reach $4.22 billion by 2030 at a CAGR of 22.5%. Growth is driven by precision medicine, rare disease research, and clinical adoption, with key players including Azenta, BGI Genomics, and GenScript.BNNU.S. bans imports from 3 Chinese biotech companies over forced labour allegationsThe Trump administration blocked shipments from BGI Group and its affiliates, alleging ties to forced labour in Xinjiang. Customs and Border Protection will bar goods from BGI Genomics and MGI Tech starting Thursday. The companies rejected the allegations, and the ban precedes an expected Xi-Trump meeting.Mexico Business NewsUS Bans Imports From Chinese Genomics Firms BGI and MGIThe US added BGI Genomics, MGI Tech, and BGI Group to the Uyghur Forced Labor Prevention Act Entity List on Oct. 28, 2026, barring their goods. The companies reported less than 2% and 8% of revenue from the Americas, respectively. The ban follows Treasury's proposed biotech investment restrictions and adds pressure to Mexico's supply chains.YahooLong Oligo Pool Synthesis for Capture Global Market Report 2026 | Capitalize on $3.31B by 2030 as Twist Bioscience, Agilent, Eurofins and BGI Scale AI-Driven Precision OncologyThe global long oligo pool synthesis for capture market is projected to grow from $1.73B in 2025 to $3.31B by 2030, a CAGR of 13.9%. Growth is driven by precision oncology, AI-driven probe design, and rising genomic diagnostics demand.Fast CompanyThe Trump administration is now blacklisting this major biotech company and its affiliates. Here’s whyThe Trump administration blacklisted BGI Group and its affiliates, barring imports from Thursday. The ban cites alleged forced labor ties in Xinjiang, with China rejecting the accusations. The move precedes a Xi-Trump meeting in Shenzhen.Business & FinancialPre-APEC US Ban On Chinese Genomic Giant Widens Biotech DecouplingThe US Department of Homeland Security added BGI Group, BGI Genomics, and MGI Tech to the UFLPA Entity List, barring their products from the US. The firms, which help Xinjiang's mass surveillance, face a presumption of forced labor. The ban takes effect Thursday and covers all imports, not just federal contracts.Punch NewspapersUS bans imports from Chinese genomics companies over forced labour concernsThe US Department of Homeland Security added three Chinese genomics companies—BGI Genomics, MGI Tech, and Shenzhen BGI Technology—to the Uyghur Forced Labor Prevention Act Entity List on Wednesday. The ban targets firms that collected genetic material to track persecuted ethnic minorities in Xinjiang. China condemned the move as baseless, while the companies denied the allegations.Nate美, '신장서 유전자 검사' 中기업 제재…中 "부당 탄압 멈춰야"(종합) : 네이트 뉴스The US added BGI Group and related firms to the Uyghur Forced Labor Prevention Act list, effectively banning their products from import. China's Commerce Ministry rejected the claims as baseless, while BGI denied involvement in forced labor. The ban adds 190 firms to the list, intensifying US-China biotech competition.